Studies heart imaging markers in people with cardiac amyloidosis
Looks at heart MRI markers of disease severity in adults with cardiac amyloidosis.
Plain-language title generated from the registry record
Registry title: Swiss Cardiac Amyloidosis REgistry (Swiss-CARE)
Key facts
- Where
- Basel, Bern, Geneva, Lausanne, Lucerne, Sankt Gallen, and Zurich, SwitzerlandSee the 7 sites
Where in Switzerland
- USBBasel, SwitzerlandTaking people
- Department of Cardiology, University Hospital Bern, Inselspital, BernBern, SwitzerlandTaking people
- HUGGeneva, SwitzerlandTaking people
- CHUVLausanne, SwitzerlandTaking people
- LUKSLucerne, SwitzerlandTaking people
- KSSGSankt Gallen, SwitzerlandTaking people
- Stadtspital TriemliZurich, SwitzerlandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Insel Gruppe AG, University Hospital Bern
- Trial code
- NCT04776824
- Record updated
- 4 November 2026
- Original description
Cardiac transthyretin amyloidosis (ATTR), caused by ventricular depositions of misfolded transthyretin, results in an infiltrative cardiomyopathy, progressing from pronounced myocardial wall thickening, diastolic and systolic dysfunction to the development of terminal heart failure. Recently, treatment options for TTR amyloidosis have become available. However costs for therapy are enormous and previous trials were not able to differentiate between patients that might benefit from treatment and those without a need for treatment.Read full original descriptionShow less
Swiss Cardiac Amyloidosis REgistry (Swiss-CARE)
Cardiac transthyretin amyloidosis (ATTR), caused by ventricular depositions of misfolded transthyretin, results in an infiltrative cardiomyopathy, progressing from pronounced myocardial wall thickening, diastolic and systolic dysfunction to the development of terminal heart failure. Recently, treatment options for TTR amyloidosis have become available. However costs for therapy are enormous and previous trials were not able to differentiate between patients that might benefit from treatment and those without a need for treatment.
the investigators study aims to determine markers, as assessed by cardiac magnet resonance imaging (CMR) feature tracking (FT) and T1- and T2- mapping, that might reliably indicate disease severity and could help to identify patients that might benefit from (ongoing) TTR stabilization treatment.
Inclusion: Confirmed diagnosis of amyloidosis w/wo cardiac involvement; General Consent.
Exclusion: Inability to give consent or existence of a written or documented oral refusal of the data subject.<18 years of age.